Formulation Development
2026 COMPANY PROFILES & CAPABILITIES
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
PURIFICATION STRATEGIES - Purification at Scale: Overcoming Chromatography Challenges for Advanced Modalities
William Sanders, PhD, explores the real-world challenges of scaling chromatography and highlights how contract development and manufacturing organizations (CDMOs) can help partners overcome them.
DRUG DEVELOPMENT - Common CMC Pitfalls in Orphan Drug Development
Hibreniguss Terefe, PhD, says although the unique challenges of orphan drug development are amplified by compressed timelines and limited patient populations, common pitfalls also serve as cautionary tales for other areas of drug development.
3D PRINTING - The Future of 3D Printing in Pharma: Aprecia’s Vision for Transformative Medicine
Kyle Smith, MBA, explains how his company, a pioneer in pharmaceutical 3D printing, has a vision for distributed, patient-centric manufacturing that could re-shape the future of medicine.
ORAL SUSPENSIONS - A New Standard in Oral Suspensions: Leveraging Novel Excipients for FDA Approval
Mary Schuster introduces a new approach to perfecting oral suspension formulations, which is centered on the strategic use of a “novel” synthetic functional excipient, magnesium aluminometasilicate (MAS).
DRUG DELIVERY - PharmaShell®: Enabling Once-Monthly Therapeutics With Atomic Precision Coatings
Anders Johansson, PhD, Polla Rouf, PhD, and Joel Hellrup, PhD, review an innovative drug delivery system that uses nanometer-thin, inorganic coatings to turn short-acting drugs into long-acting injectables.
INJECTABLE DEVICES - Delivering Tomorrow’s Injectables to Patients Today: Responding to a New Era of Demand With Purpose-Built Capabilities
Tommy Schornak examines how evolving therapeutic modalities, delivery systems, and regulatory expectations are reshaping the fill finish landscape.
PLATFORM TECHNOLOGY - Developing Innovative Solutions to One of the Top Public Health Threats: Antibacterial Resistance
Jennifer Schneider, PhD, believes immunotherapy holds the potential to revolutionize the treatment of “hard to treat,” chronic, and often recalcitrant infections.
Bora Pharmaceuticals & Corealis Pharma Forge Strategic Alliance to Deliver Seamless, End-to-End Oral Solid Dose Development
Bora Pharmaceuticals Co., Ltd. and Corealis Pharma Inc. have entered into a strategic alliance to provide end-to-end services for oral solid dose (OSD) development and…
Enterprise Therapeutics Publishes Results of Phase 1 Study of a Novel Inhaled ENaC Blocker for Treatment of Cystic Fibrosis
Enterprise Therapeutics Ltd recently announced the publication of a peer reviewed study in the Journal of Cystic Fibrsosis1. The paper, titled ETD001, a long-acting inhaled…
Spinogenix Reports Evidence of Rapid, Sustained Cognitive Improvement in Alzheimer’s Patients From Phase 2a Trial of TAZBENTETOL
Spinogenix, Inc. recently announced encouraging results from its completed Phase 2a trial evaluating Tazbentetol (formerly named SPG302) for the treatment of Alzheimer’s disease (AD). Once-daily…
TScan Therapeutics Announces Positive Updated Data From Phase 1 Heme Trial
TScan Therapeutics, Inc. recently announced updated results from the ongoing ALLOHA Phase 1 trial (NCT05473910) of TSC-101 in patients with heme malignancies undergoing allogeneic hematopoietic…
Rigel Presents Updated Data From Ongoing Phase 1b Study Evaluating R289 in Patients With Lower-Risk MDS
Rigel Pharmaceuticals, Inc. recently announced updated data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual…
Kymera Therapeutics Announces Positive Results From Phase 1b Clinical Trial of a First-in-Class Oral STAT6 Degrader in Patients With Moderate to Severe Atopic Dermatitis
Kymera Therapeutics, Inc. recently announced positive clinical results from the BroADen Phase 1b atopic dermatitis (AD) clinical trial of KT-621, its first-in-class, oral STAT6 degrader…
Kelun-Biotech & Crescent Biopharma Announce Strategic Partnership to Develop & Commercialize Novel Oncology Therapeutics
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Crescent Biopharma, Inc. recently announced they have entered into a strategic partnership to develop and commercialize oncology therapeutics, including…
Quotient Sciences & Intrepid Labs Form Strategic Partnership to Accelerate AI-Guided Formulation Development
Quotient Sciences and Intrepid Labs recently announced a ground-breaking multi-year strategic partnership to advance the use of artificial intelligence (AI) in early drug development. Under the…
Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea
Incannex Healthcare Inc. recently announced the US FDA has granted Fast Track designation for IHL-42X, the Company’s oral fixed-dose combination product candidate for the treatment…
Leadership Transition at Vetter: Thomas Otto Retires
Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), recently announced the retirement of its Managing Director Thomas Otto after more than 35 years…
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
Protara Therapeutics, Inc. recently announced updated interim data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with carcinoma in situ or…
Evonik Names New President for the Americas Region
Evonik, one of the world’s leading specialty chemicals companies, has appointed long-time Evonik executive Elias Lacerda President of the Americas region, effective February 1, 2026.…
